We inform you that as of October 2024, Leitat, through its proprietary company MedTech Innovation on Advanced Medicine S.L.U. (MedTech Barcelona), has successfully acquired ReadyCell S.L.’s branch of activity as well as all employees dedicated to the development and commercialization of the ready-to-use cell-based plates for in vitro ADME-Tox and DMPK studies.
This operation stems from a long-standing collaboration between Leitat and ReadyCell, in which Leitat has been involved since its inception. Together, we have jointly developed the products that ReadyCell now successfully commercializes globally. This agreement aligns with the technology center’s commitment to bolstering its biotechnology development and innovation branch.
Importantly, this transition will not affect our commitments with our clients, that can continue to rely on the same high-quality products, brands, and service standards expected from us. Our dedication to supporting our client needs remains unwavering, and we look forward to offering expanded services as part of our future growth.
We invite you to stay tuned for new communication channels that will be activated soon, as the ReadyCell website will transition to MedTech Barcelona.
Thank you for your continued support as we enter this thrilling new chapter!
